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Background:  African American men who have sex with men (MSM) represent 37% of 
the HIV incidence among all MSM and young Black MSM observed a significant increase of 
48% in new infections during 2006-2009. There were 6,500 infections in Black MSM aged 13-
29 exceeding the number of infections of White MSM aged 13-29 and 30-39 combined. In 2010, 
results from the Global iPrEX clinical trial showed 44% efficacy of oral pre-exposure 
prophylaxis among MSM. The implementation of PrEP as a HIV prevention tool may have 
positive implications in reducing the disparity of HIV infection among Black MSM. 
Methods: Participants were recruited and sampled for an online survey using the social 
networking sites Facebook and Twitter. Eligibility for participation was contingent upon self-
reported response as Black/African American, an MSM, HIV negative or unaware of HIV status, 
and over 18 years of age. Informed consent was obtained. Behavioral data was collected from 
participants on sexual behaviors, HIV testing, and self-perceived susceptibility to HIV infection. 
Participants were asked specifically their knowledge of PrEP and likeliness of using PrEP to 
reduce risk of HIV infection. 
Results: The sample pre-eligibility included 178 respondents. 20.5% (32) respondents 
reported being HIV positive. After eligibility was determined 99 respondents were included in 
the analysis. 56.4% of the sample reported having little or no knowledge of PrEP yet would use 
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PrEP to reduce their risk of HIV infection. Age was the strongest indicator of all the independent 
variables on PrEP acceptance being statistically significant in all models of the regression 
analysis.  
Conclusions: Contrary to the original hypothesis, an inverse relationship between PrEP 
knowledge and acceptance was ascertained in the current study. Some possible explanations for 
this interesting finding are that respondents were unaware of the risks and benefits of pre-
exposure prophylaxis and were concerned about preventing themselves from contracting HIV. 
Also if respondents were to use PrEP, it would likely have to be at little or no individual out of 
pocket costs. There are a number of factors influencing such high acceptance of PrEP among 
Black MSM and the current study was able to ascertain some of these factors. These findings 
have public health significance to the current epidemiology of HIV infection in the United States 
and further prevention efforts. 
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1.0 INTRODUCTION 
 
 
 
 
 
 
More recently, extensive research has been conducted on biomedical interventions to 
human immunodeficiency virus (HIV) prevention to elucidate the efficacy of chemoprophylaxis 
in preventing the transmission of HIV in HIV negative individuals. This paper will provide 
context of the HIV transmission and the epidemic in the United States, followed by an overview 
of the disparity of HIV infection experienced by African Americans and African American 
MSM. Next, there will be a review of relevant literature on HIV pre-exposure prophylaxis 
followed by and evaluation of the participation of African American MSM in HIV biomedical 
and prevention research. Findings will be presented from the current study which surveyed 
African American MSM on their knowledge and attitudes of HIV pre-exposure prophylaxis. 
Finally, the author will offer recommendations for HIV prevention policy and suggestions for 
integrating pre-exposure prophylaxis into the existing HIV prevention toolbox. 
More research and information must be gathered on PrEP before it can be disseminated to 
HIV negative Black MSM as an HIV prevention strategy. Very little information exists on the 
knowledge and attitudes that Black MSM have on PrEP. Throughout this paper, PrEP refers to 
oral pre-exposure prophylaxis, not topical microbicides. There are several questions that the 
author hopes the current study may answer. What is the knowledge that Black MSM have on 
PrEP? How likely are Black MSM to take a pill daily to reduce their risk of HIV infection? What 
is the individual perceived susceptibility of Black MSM to HIV/STI infection and are they even 
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concerned about the high rates of infection in the Black MSM community? What are the 
circumstances for under which Black MSM have unprotected receptive anal intercourse? A goal 
of this thesis research is to provide insight and possible policy recommendations on how PrEP 
could possibly be used amongst Black MSM. It is hypothesized that if Black MSM have little 
knowledge of PrEP and lower perceived susceptibility to HIV infection, they would be less 
likely to use PrEP to reduce their risk of HIV infection. 
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2.0 LITERATURE REVIEW 
 
 
 
 
 
 
In 1981, the world changed as the HIV pandemic was brought to the public’s forefront. 
Little was known about HIV in the beginning however, one thing was evident; people were dying 
and dying fast. It appeared that HIV only affected gay men, but soon thereafter heterosexuals 
began to become infected as well. We now retain extensive information on the virus; the mode of 
transmission, the biology and immunology, and how to treat the virus. 
 
 
 
 
 
2.1 HIV OVERVIEW 
 
 
 
 
 
 
 
 
 
2.1.1 HIV Epidemiology 
 
 
 
 
HIV can only be transmitted if one comes in contact with infected blood, semen, vaginal 
secretions, and breast milk. In the worldwide context of HIV infection, unprotected heterosexual 
intercourse is the predominant mode of transmission for the virus (The Henry J Kasier Family 
Foundation, 2007). Unprotected anal and vaginal intercourse represents greater than 80% of the 
annual HIV incidence in the United States (Centers for Disease Control and Prevention, 2012). 
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Other modes of HIV transmission include the perinatal transmission, and intravenous drug use 
through needle sharing.  
HIV transmission can be prevented through the consistent and correct use of condoms. 
Condom availability and accessibility has significantly increased, with individuals being able to 
access them free of charge from health departments and public health agencies. Despite the 
gamut of information on HIV infection, the incidence in the US has remained relatively stable at 
about 50,000 new infections per year (CDC, 2011). It is estimated that 1 in 5 or 20% of 
individuals who are HIV infected in the US are unaware of their infection and responsible for 
roughly half of the annual incidence (CDC, 2012). The aforementioned statistic enumerates the 
implications of HIV testing and being aware of HIV status. HIV tests only test for HIV 
antibodies, therefore an HIV infected person who is seroconverting from negative to positive is 
infectious, yet may fail to test positive on a test if he/she had in fact been tested while they were 
within what is known as the window period  
It is during the window period that HIV infected individuals are oftentimes unaware of 
their status yet are able to transmit the virus to partners. This brings up the importance of getting 
an HIV test within three to six months after a high risk exposure. When an individual is in the 
process of HIV seroconversion, the symptoms of acute HIV infection may mimic common cold 
or flu symptoms which cause extreme difficulty in recognizing infection and accessing testing 
and treatment. In fact, some individuals who are infected do not become aware of their infection 
until the disease progression has reached Acquired Immunodeficiency Syndrome (AIDS). 
Essentially, HIV testing goes hand in hand with prevention and may have implications on the 
applicability of PrEP to individuals at risk for HIV infection. 
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2.1.2 HIV Diagnostic and Prognostic Indicators 
HIV being an infectious disease has different physical and biological manifestations in 
the individuals infected. The disease progression and prognosis is multifactorial; time of 
diagnoses, linkage into care and treatment, medical adherence, comorbidities and other factors 
affect an individual’s response to HIV infection. Two prognostic indicators that are used in HIV 
infection are the CD4 cell count and the viral load. The CD4 count is the measure of the immune 
function of the infected person. A lower CD4 count represents poorer immune function and 
increased susceptibility to HIV opportunistic infections such as pneumocystis jirovecii 
pneumonia and Kaposi’s sarcoma which result in further disease complications. A person in the 
US is diagnosed as having AIDS if his /her CD4 T cell count drops below 200 per milliliter of 
blood. Once an individual is diagnosed as having AIDS, the CD4 count may return to over 200. 
However, that individual is still classified as a person with AIDS (CDC, 2011). The viral load is 
the indicator of how much virus is in the infected person’s blood. The higher number of copies of 
virus, the more infectious the individual in terms of transmitting HIV infection to others  
The gold standard for an HIV treatment is to reduce the patient’s viral load to 
“undetectable” that is having fewer copies than can be detected by the viral load assay. Having a 
viral load that is undetectable significantly reduces the risk of transmitting the virus in 
comparison to someone who has a higher viral load. The relationship between viral load and 
CD4 count is inverse. Typically, an HIV positive individual with a higher viral load usually has a 
lower CD4 count.  
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2.1.3 Disparities in HIV Infection  
The National HIV/AIDS Strategy suggests a need to end segmented prevention efforts in 
MSM and African American populations to address the HIV disparity in Black MSM (National 
HIV/AIDS Strategy, 2010). This paper will address the health disparity of HIV infection 
amongst African Americans in the United States, specifically African American MSM. These 
men are the highest at risk population in the U.S. accounting for roughly half of the HIV 
prevalence and more than half of the annual incidence estimated at 28,700 new infections (CDC, 
2011). African American MSM represent 37% of the HIV incidence among all MSM and young 
Black MSM observed a significant increase of 48% in new infections during 2006-2009; there 
were 6,500 infections in Black MSM aged 13-29 exceeding the number of infections of White 
MSM aged 13-29 and 30-39 combined (CDC, 2011). “Unprotected anal intercourse (UAI) is the 
single most important risk factor for HIV transmission among MSM (Millet, et al., 2006).” There 
are some estimates that unprotected receptive anal intercourse (URAI) is approximately 20 times 
a greater risk as opposed to unprotected vaginal sex because the rectal lining is thinner and less 
acidic than the vaginal lining (Microbicide Trials Network, 2011). As a result of the biological 
differences between the anus and the vagina, HIV can penetrate rectal tissues easier and 
penetrate the host’s immune system. Despite therapeutic advances in HIV care that have been 
facilitated by the use of highly active anti-retroviral therapy(HAART), disease progression and 
mortality for HIV positive Black MSM have fared worse in comparison to White MSM.  
In the context of the HIV epidemic among Black MSM, several causal factors contribute 
to higher incidence including testing patterns and awareness of status. Having a prior or current 
sexually transmitted infection enhances the susceptibility and transmission of HIV infection 
(Millett, et al., 2006). According to CDC STD surveillance reports, Black MSM were more 
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likely than any other group of MSM to report ever having a urethral chlamydia infection, urethral 
gonorrhea, and pharyngeal gonorrhea infection, contributing to the racial disparity of HIV 
infection among MSM (Millett, et al., 2006). Another factor contributing to higher HIV 
incidence amongst Black MSM alludes to testing and awareness of status. Several studies that 
have corroborated evidence that Black MSM obtain HIV testing less frequently than MSM of 
other races and are diagnosed later in the disease progression. It is estimated that approximately 
116,750 people in the African American community are unaware of their HIV infection (CDC, 
2011). Lack of awareness of status among Black MSM does not seem to be influenced by age. In 
one study 91% of the young Black MSM aged 15-22 was unaware of their HIV infection as 
compared to only 69% of Latino MSM and 60% of White MSM. In a similar study that recruited 
older MSM age 18-81, 64% of HIV positive Black MSM were unaware of their status as 
compared to 18% of Latino MSM and 11% of White MSM (Millett, et al., 2006). Prior studies 
show that being aware of HIV status can lead to sexual behavioral risk reduction. Findings from 
the 2008 National HIV Behavioral Surveillance System showed that young Black MSM aged 15-
22 had higher HIV prevalence (14.1%) in contrast to young Latino and White MSM, 6.9% and 
3.3% respectively (Phillips, et al., 2011). At the baseline, 37% of the Black MSM reported 
having UAI in the previous 6 months. At the conclusion of the 12 month follow-up, participants 
who were new to care were more likely to not have multiple sexual partners and UAI as 
compared to participants who had already been in care (Phillips, et al., 2011). Black MSM are 
less likely to be tested frequently for HIV which results in a lack of awareness of status, can 
result in higher risk taking behaviors than someone who is aware of their status, and ultimately 
higher HIV prevalence amongst Black MSM (Millett, et al., 2006) Also contributing to the HIV 
epidemic in Black MSM is the social determinants of HIV such as lower socioeconomic status, 
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racism, internalized and external homophobia, religious persecution, and negative medical 
perceptions (CDC, 2011). With African American MSM currently being at the highest risk for 
HIV infection in the U.S., effective interventions and strategies for Black MSM must explore 
both behavioral and biomedical approaches of alleviating the HIV epidemic within this 
community. 
 
 
 
 
 
2.2 PRE-EXPOSURE PROPHYLAXIS 
 
 
 
 
 
 
 
2.2.1  Pre-Exposure Prophylaxis Pharmacology 
 
 
 
 
The CDC has begun to implement “high impact prevention” which targets the highest 
risk populations and areas of highest HIV prevalence. Currently in the US, Black MSM are 
observing significant increases in HIV infection while other racial and sexual groups have 
observed stable or decreasing incidence. PrEP that has been approved for use in MSM involves 
the medicalization of HIV negative individuals with the HIV medication Truvada (emtricitabine 
+tenofovir). “Antiretroviral drugs are currently used for HIV prevention in other settings, 
including after high risk HIV exposures such as needle sticks (post exposure prophylaxis [PEP]), 
post rape or high risk sexual exposures (non-occupational PEP), or for prevention of mother to 
child   transmission   (Anderson,   et   al.,   2010).”   Truvada   belongs   to   the   class   of   HIV 
pharmaceuticals known as nucleoside reverse transcriptase inhibitors (NRTIs) whose objective is 
to inhibit the viral replication stage of the HIV virus and limit the copies of that is created in an 
infected host (Gilead Sciences, 2011).  Anderson et al. (2010), asserts that an antiretroviral drug 
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selected for prophylaxis should have limited drug-drug or food-drug interactions, proven safety 
and efficacy, lower dosing, and minimum risks for HIV drug resistance. It was for these reasons 
that Truvada was selected for the iPrEX trial because of its excellent record for safety and 
efficacy. Gilead Sciences, the producer of Truvada and Tenofovir (TDF) estimate that currently 
at least 1.5 million people worldwide are using a Tenofovir based regimen (National Institute of 
Allergy and Infectious Diseases, 2010) 
Considerations of PrEP drug toxicity and efficacy must be addressed. Anderson et.al 
asserts that no surrogate marker exists for optimal dosage or drug concentration in terms of PrEP 
resulting in subjective analysis of variability in drug effectiveness and toxicity (Anderson, et al., 
2010) In other words, even with proven safety and efficacy, there is no clinical marker that 
enumerates a specific amount of drug concentration that must be present for a prophylactic 
effect. This brings up concerns since medications are not metabolized the same by everyone and 
it is possible that one person would need a higher dosage or concentration of drug to be effective. 
Distribution of emtricitabine and tenofovir to tissues necessary for HIV prophylaxis has been 
proven with detectable drugs levels in the vagina being observed within 2 hours after dosage and 
accumulation in semen 4 times faster than in plasma (Anderson, et al., 2010). Tissue absorption 
is essential to PrEP effectiveness as the objective is to prevent the invasion of the HIV virus into 
tissues exposed during high risk behaviors such as unprotected sex. 
The toxicity of Truvada is not a major concern however, new or worsening renal 
insufficiencies have been documented which bring up the necessity for pre-screenings prior to 
beginning a PrEP regimen. Gender differences may exist in the pharmacology and metabolism of 
NNRTIs. One study of women and men receiving indinavir, zidovudine, and lamivudine found 
that lamivudine concentrations were higher in women (Anderson, et al., 2010). Another study of 
10  
tenofovir plus lamivudine with either nevirapine or lopinavir/ritonavir observed 
lamivudine/tenofovir concentrations that were higher in women than in men as well (Anderson, 
et al.,2010). Despite these studies being relatively small, the findings bring up some safety 
concerns and future research is warranted. If it is found through further research that gender or 
racial differences exists in drug metabolism and concentration, formal PrEP recommendations 
would need to be formulated to reflect these differences. 
 
 
2.2.2 The Global iPrEX Clinical Trial 
 
 
 
 
In December of 2010, the findings from the Global iPrEX study, a clinical trial evaluating 
the efficacy of oral HIV pre-exposure prophylaxis sex within transgendered women and MSM 
was published. The study took place at 11 different sites in Ecuador, Peru, South Africa, Brazil, 
Thailand, and the US. The US had two of the 11 sites in Boston, MA and San Francisco, CA. 
Truvada was chosen as the study drug because of the protective effect against HIV in its two 
active drugs, emtricitabine and tenofovir in mice transplanted with human immune cells and non- 
human  primates  (Grant,  et  al.,  2010).  From  all  of  the  study  sites,  4,905  participants  were 
screened for participation in the study with a total of 2,499 enrolled in the study. Participation in 
the study was contingent on the participant being over the age of 18, being born as a male, HIV 
negative, and at high risk for HIV infection. Some of the parameters that were used to access 
high risk for HIV infection were unprotected anal intercourse with a partner of unknown positive 
HIV status within 6 months prior to screening, unprotected receptive anal intercourse within 12 
weeks prior to screening, and or transactional sex. 59% of the participants in the treatment arm 
and 60% in the placebo arm reported having URAI within 12 weeks of screening which has been 
described as very high risk for HIV infection (Grant, et al., 2010). Participants who were at high 
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risk for Hepatitis B infection (HBV) were offered the vaccine with 94% acceptability (Grant, et 
al., 2010). 13 individuals were enrolled with chronic HBV infection and any acute HBV 
infections were treated. Excluding HIV positive individuals from participating in the study was 
critical to the design because including an HIV positive individual would negatively affect the 
internal validity and generalizability of the results. Any individuals who came up positive during 
the treatment process and during the clinical trial were linked into care and treatment. 
The iPrEX trial design was a randomized, controlled, double blind trial meaning that 
participants were randomly assigned to either the treatment group (Truvada) or placebo group. 
Neither the participants or the researchers were aware of which arm of the study in which they 
were included. Follow up varied by participant however, the maximum time that a participant 
was followed up was 2.8 years. From baseline to follow up, all participants received a range of 
prevention services during every scheduled visit which included diagnoses and treatment of 
symptomatic sexually transmitted infections, rapid HIV testing, risk reduction counseling, and 
condoms. It was stressed to the participants to continue conventional preventative measures 
against HIV infection such as condom use since they were unaware of the specific study arm. 
This aspect of the study design addresses possible risk compensation behaviors that could arise 
in some participants such as if they presumed they were in the treatment arm and discontinued 
condom use. During follow up intervals, participants received the diagnoses and treatment of 
asymptomatic sexually transmitted infections, pill distribution and count, medical adherence 
counseling, and medical history. The comprehensive prevention package that iPrEX participants 
received was important to the integrity, ethics, and efficacy of the trial however, efficacy does 
not equate to real world effectiveness. 
12  
A smaller percentage of the iPrEX participants in either the placebo and treatment arm 
were enrolled at the US sites. Boston had 44(3%) participants in the treatment arm and 44(4%) 
participants in the placebo or 7% of the entire cohort. The San Francisco site enrolled 60 
participants in both study arms for a participation rate of 5% in each arm and 10% of the cohort. 
Overall just 8% of participants in the treatment arm and 9% in the placebo arm were from the 
US. When the demographic of the participants are examined, a majority of the iPrEX participants 
were Hispanic, accounting for 72% and 73% in the treatment and placebo arms respectively. 
Blacks had relatively low recruitment and participation in the iPrEX trial accounting for 9% in 
the treatment arm and 8% in the placebo arm. 
Among MSM, when subjects in the treatment group took once, daily oral Truvada, there 
was a 44% reduction in HIV infection as compared to the control group (Grant,et al., 2010). 
Throughout the entire trial, there were 100 HIV infections, 36 in the Truvada arm and 64 in the 
placebo arm. Variance in efficacy of prophylaxis among participants in the treatment group was 
monitored through medical adherence or rate of pill use which was recorded based on pill counts, 
self-reports, and distribution records at 81% of visits where efficacy was 50% (Grant, et al., 
2010). Longer follow up and the rate of pill use did not result in significant changes in efficacy 
however, it is important to note that efficacy was higher (58%)  in participants who reported 
having URAI at least 12 weeks prior to screening in comparison to those who did not (Grant, et 
al., 2010). These results show that efficacy was higher for the individuals that were of higher risk 
for HIV infection. The observed difference may not be attributable to just the drug but other 
factors such as risk reduction. Adherence appeared to have a positive impact on efficacy with 
73% reduction in infections among participants with pill use greater than 90% (Grant, et al., 
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2010). Similar to HIV treatment, medical adherence is vital to drug effectiveness and protective 
benefit, therefore it is not surprising that the results from the iPrEX trial corroborated that. 
Some of the concerns of conducting the trial were possible onset of drug resistance, drug 
absorption and  prophylactic  effect, safety,  and differences in  efficacy amongst  participants. 
There were no observed differences in efficacy between the treatment and control groups based 
off of region, race or ethnicity, male circumcision, educational attainment, alcohol use or age 
(Grant, et al., 2010). In other words, the variables and factors mentioned did not confound the 
efficacy of the pre-exposure prophylaxis. These findings are significant for the external validity 
of the results and the generalizability to MSM regardless of certain demographic factors. Drug 
absorption was essential to the efficacy of the study results as well. When participants were 
screened for the drug, an assay was used that could detect whether dosing had taken place within 
14 days of the screening. Out of 34 of the participants in the treatment arm who became HIV 
positive during the course of the study, 3 of the participants had detectable levels of at least 
either emtrictabine or tenofovir (Grant, et al., 2010). Once again the issue of adherence is 
brought up. PrEP cannot be used as a “morning after” pill, efficacy and higher levels of drug 
absorption can be achieved by adherence to daily dosing requirements. It is assumed that the 
individuals in the treatment arm who had detectable drug levels may have had poor adherence to 
the  regimen  which  lowered  prophylactic  effect.  Another  concern  of  the  iPrEX  trial  was 
participant risk compensation which is engaging in unsafe sexual behaviors while on treatment. 
The study found that high risk behavior decreased significantly after enrollment and remained 
lower than baseline throughout the trial, condom use increased, and UAI decreased (Grant, et al., 
2010). Concerns of drug resistance to either of the drug components in Truvada were also a 
concern in the iPrEX study. Each participant who was determined to be HIV seropositive was 
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screened for resistance to emtricitabine and tenofovir. Out of 100 infections that occurred in the 
treatment and placebo arms of the study, no drug resistance from either component was detected 
nor was there any delay of seroconversion amongst the participants in the treatment group 
(Grant, et al., 2010). Other than minor side effects such as nausea, there were 41 cases of 
elevated serum creatine, with an additional 2 elevations in creatine level for a total of 43 adverse 
events (Grant, et al.,2010). It is essential that drug safety was ensured for the participants and 
anyone  using  Truvada.  With  Truvada  being  in  the  NRTI  class,  having  high  acceptability, 
efficacy, and low dosing, it would be a major setback in treatment options if drug resistance were 
to arise. 
Despite some of the promising results of the iPrEX trial, there are some limitations that 
should be discussed. No biomarker exists for the minimum level of drug absorption for 
prophylactic effect. Further research must be conducted into how much drug must be present for 
effectiveness. In spite of all of the prevention services that were offered to participants, the 
feasibility and practicality of replicating these findings among high risk populations in a real 
world setting is brought into question. The iPrEX study showed that some commonly used 
variables such as age, race, and region did not affect the efficacy of the study but it has yet to be 
seen if these findings will be replicated in other studies. Further research must be conducted on 
the acceptability and adherence of PrEP among high risk populations as well as any long term 
effects that may arise from PrEP use. 
 
 
2.2.3 Other MSM PrEP Trials 
 
 
 
 
The iPrEX trial was the basis for which current recommendations for PrEP have been 
established. It is important to note other PrEP trials that have been conducted or planned among 
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MSM populations. In 2010, the CDC completed a U.S. Tenofovir Extended Safety Trial to look 
at the safety of daily oral PrEP amongst MSM. The sites were located in Atlanta, Boston, and 
San Francisco. 400 HIV negative MSM were recruited based on self-reports of UAI within 12 
months prior to screening. The trial was double blind trial and participants were randomized to 
one of four study arms. In two of the arms, participants received either Tenofovir or a placebo 
immediately following enrollment. In the other two arms, participants received Tenofovir or a 
placebo 9 months after enrollment. The results of the trial have yet to be published however, 
preliminary findings suggests that there were no significant differences in sexual risk behaviors 
between the two study arms at enrollment and the two arms 9 months after enrollment and no 
adverse  events  were  reported  amongst  participants  (CDC,  2010).  The  CDC  trial  was 
implemented to evaluate the effectiveness of PrEP, not efficacy as was evaluated in the iPrEX 
study. Despite no major differences in risk compensation between the study arms, participants 
were provided with a prevention package which included STD testing and treatment, HIV 
counseling and education, and condoms throughout the study. 
The HIV Prevention Trials Network (HPTN) 067 began in late 2011 and recruited 180 
 
MSM to evaluate PrEP adherence. Participants were randomized to one of several treatment 
arms; Truvada will be taken either daily, twice a week and after sex, and before and after sex 
(AVAC, 2011). The NEXT-PrEP study or HPTN 069 is scheduled to begin in early 2012 and 
will have 400 MSM participants and evaluate the safety and tolerability of daily oral Maraviroc 
or Maraviroc in combination with Tenofovir or Truvada. This trial is being conducted using 
Maraviroc as a study drug because some evidence points to that Maraviroc may be safer than and 
just as effective as Truvada. The iPrEX Open Label Extension trial is scheduled to begin in 2013. 
This trial will evaluate the safety and adherence of once a daily oral Truvada amongst iPrEX 
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participants (AVAC, 2011). PrEP demonstration projects across the U.S. are being planned with 
one project at the University of California at Francisco already being awarded funding from the 
National Institutes of Health in which 300 participants will be recruited from sites in San 
Francisco and Miami. The study is intended to evaluate monitoring and programming for PrEP 
(AVAC, 2011). The Microbicide Trials Network (MTN) 017 study is a phase II clinical trial that 
is to be conducted starting in 2012 recruiting 120 MSM from sites in Peru, South Africa, 
Thailand, and the US (AVAC, 2011). The MTN study will not only be evaluating the safety, 
adherence, and drug detection in relevant body fluids from oral PrEP, but from microbicides as 
well. Participants will be required to take oral Truvada depending on the arm of the study 
randomization. The ANRS IPERGAY study is scheduled to begin in 2014 at sites in Canada, 
France, and other European countries to be announced. In this study of MSM, the safety and 
efficacy of Truvada taken intermittently and before and after sex will be evaluated (AVAC, 
2011). There are many PrEP trials and studies which are ongoing or planned for the future. There 
is little information on the efficacy of PrEP amongst MSM aside from the iPrEX trial. In order to 
ascertain the effectiveness and practicality of PrEP use among MSM of different races/ethnicities 
and regions, more demonstration projects and research is needed. In the meantime, we must wait 
for the ongoing studies to be completed so that many factors around PrEP such as efficacy, 
acceptability, adherence, and risk compensation can be evaluated contribute to the evidence base 
of the iPrEX results. From the research that is conducted, formal and tailored recommendations 
can be made for PrEP use among MSM. 
17  
2.2.4 PrEP Trials in Other High Risk Populations 
 
 
 
 
PrEP trials have not only been conducted and planned for MSM, but other high risk 
populations as well including intravenous drug users (IDUs) and heterosexual women. Even 
though results among these populations cannot be extrapolated to MSM, they are important to 
note. The Bangkok Tenofovir Study is a CDC led clinical trial that recruited 2,400 IDUs in 
Thailand and observed the safety and efficacy of daily oral Tenofovir. Results and publications 
from this study are pending. To reiterate what was stated earlier, it was shown that (emtricitabine 
+ tenofovir) or Truvada was proven to be more efficacious than either medication alone. If 
Tenofovir is proven to be efficacious amongst this population of IDUs in Thailand, the CDC will 
further assist in providing access for participants to PrEP. The TDF2 study was conducted in 
1,200 young heterosexual men and women living in Botswana in which participants received 
daily oral Truvada. The purpose of the study was to evaluate the efficacy, safety, and adherence 
among participants; the study has concluded and results show that daily oral Truvada reduced the 
risk of HIV infection by an average of 62.6% in young heterosexual men and women (AVAC, 
2011). Another PrEP study was the Partners PrEP study which recruited 4,700 serodiscordant 
heterosexual couples in Kenya and Uganda to evaluate the safety and efficacy of daily oral 
Tenofovir and Truvada. An HIV discordant couple is a couple in which one individual in HIV 
infected and the other individual is HIV negative. In the Partners PrEP study, the HIV negative 
partners  received  either  the  daily  oral  Truvada  or  Tenofovir.  Preliminary  results  from  the 
Partners PrEP study showed that daily oral Tenofovir led to a 62% reduction in HIV infections as 
compared to a 73% reduction in infections from daily oral Truvada (AVAC, 2011). A 
continuation/follow up phase III trial to the Partners PrEP study is scheduled to begin in 2013. 
Participants who were randomized into the original treatment arms will continue daily oral 
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prophylaxis. Participants who were originally randomized into the placebo arm will be 
randomized to either the daily oral Tenofovir or the daily oral Truvada. The VOICE study 
recruited 5,000 heterosexual women in South Africa, Malawi, Uganda, Zambia, and Zimbabwe 
who  were  to  be  a  part  of  different  study  arms.  Treatment  arms  included  participants  who 
received daily oral Tenofovir, daily oral Truvada, and daily Tenofovir gel microbicide. Due to 
there being no proven benefit from daily oral Tenofovir, that arm of the study was discontinued 
with the study going forward with the other two treatment arms (AVAC, 2011). 
The FEM-PrEP trial which was composed of 3,900 heterosexual women recruited from 
sites in Kenya, Malawi, South Africa, Tanzania, and Zambia. The FEM-PrEP trial was similar in 
iPrEX in that the safety and efficacy of oral daily Truvada was to be evaluated. The FEM-PrEP 
trial was discontinued because during the trial it was shown that there was no observed benefit 
from the women enrolled in the treatment arm taking daily oral Truvada in comparison to 
participants in the placebo arm (AVAC, 2011). 
 
 
2.2.5 MSM PrEP Knowledge, Perceptions, and Acceptance 
 
 
 
 
In conducting the literature search, it was important to find any behavioral analysis 
conducted on MSM knowledge and attitudes on PrEP in addition to the actual biomedical 
interventions. There were few published articles found in the literature which addressed MSM 
knowledge and attitudes of PrEP. Limited information exists in the literature on the knowledge 
and attitudes that Black MSM have on PrEP. Studies which have retained Black MSM had 
relatively low amounts of participants, similar to the Global iPrEX study. One study recruited 
MSM from two New York City bath houses and recruited 54 MSM. 63% of the survey 
respondents reported having unprotected sex with another male within the previous 90 days and 
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7% reported having unprotected sex with a known HIV positive male partner. Only 36% of the 
survey respondents reported awareness of non-occupational post exposure prophylaxis (nPEP) or 
PrEP (Mehta, et al., 2011). The study found awareness of PrEP and nPEP regardless of 
race/ethnicity, educational attainment, and other factors was correlated with having a primary 
care physician who was aware of their sexual behaviors (Mehta, et al., 2011). 
Irvin, et al. (2011), conducted an online survey of MSM recruited from Facebook and 
BlackGayChat and which had a participant demographic of 73% White, 7% African American, 
and 12% Hispanic. In this particular survey, participants were educated about the efficacy of 
PrEP and then asked about their perceived sexual behaviors if they were to use or not use PrEP. 
Out of 1,155 respondents, the mean age was 33 years old and it was concluded that 75% of the 
respondents would continue to use condoms regardless if they were on PrEP or not (Irvin, et al., 
2011). Despite the significant number of survey respondents who would continue safer sexual 
behaviors, 39% of participants reported less perceived risk of HIV infection from URAI on 
PrEP. The implications of these numbers are that if MSM have lower perceived risks of HIV 
infection while on PrEP they may be more likely to engage in higher risk sexual behaviors for 
HIV transmission. Conversely, Brooks et al., (2011) recruited 25 HIV negative MSM who were 
a part of a serodiscordant relationship and evaluate their perceptions on PrEP.in in which 60% of 
the respondents indicated likelihood of discontinuing condom use with their HIV positive partner 
if they were on PrEP. Despite the relatively small sample size, these findings provide some 
guidance on how PrEP should be used amongst serodiscordant couples. According the results, 
HIV negative partners in a serodiscordant couple would be likely to engage in high risk sexual 
behaviors and unprotected sex while on PrEP which is not the intended purpose of PrEP. A 
sample of 180 HIV negative MSM were recruited in New York City which found that 70% of 
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the respondents would use PrEP contingent upon 80% efficacy in preventing HIV infection and 
among respondents who reported that they would use PrEP, 35% reported a reduction in condom 
use (Golub et al., 2010). At the time of publication, the Global iPrEx results had not yet been 
released which showed 44% PrEP efficacy in reduction of HIV infection. It is possible that had 
respondents known PrEP efficacy at the time of the study, less individuals would be likely to use 
PrEP. 
Another online survey on likeliness and knowledge of PrEP was conducted by Sullivan et 
al. (2011), recruited 1,333 self-identified HIV negative MSM, 71% which were white, 13% 
Hispanic, and 8% black. The survey found that 29% of the participants had not heard of the 
iPrEX study results and that nonwhite participants (71-78%) were more likely to use PrEP to as 
opposed to only 64% of white participants (Sullivan, et al., 2011). Whiteside, et al. (2011), 
recruited participants for a survey on PrEP from a STD clinic in South Carolina, which is located 
in a region of the country heavily affected by HIV/AIDS. 89% of the participants were African 
American and 56% male; 8% of the participants were either homosexual or bisexual. It was 
undetermined whether or not these participants were MSM from the analysis. Only 9.4% of the 
358 respondents reported having any knowledge of PrEP and when participants were asked to 
rate their difficulty in being able to use condoms and take a daily bill to prevent HIV infection, 
38% of the participants strongly agreed that they would be capable of doing so and 32% agreed 
that they would have some difficulty (Whiteside, et al., 2011). Despite there being a smaller 
sample size of homosexuals in the sample population, homosexuals were significantly more 
likely  to  report  awareness  of  PrEP  (Whiteside,  et  al.,  2011).  These  findings  may  have 
implications on how information about PrEP is disseminated among different populations. 
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Barash and Golden conducted a survey on PrEP amongst MSM at a gay pride event in 
Seattle, Washington and found that 44% of the respondents would take PrEP daily if reduced 
their risk of infection. There were no observed differences in sexual risk behaviors and PrEP use 
(Barash & Golden, 2010). A study conducted at the Fenway Institute in Boston, Massachusetts 
used peer recruitment and subsequent incentives for a survey and data collection on PrEP 
awareness. 227 participants were recruited with a mean age of 40 and 44% of the participants 
being Black. In the informed consent process of the survey, participants were provided a 
statement on what PrEP was and it’s intended use. The study concluded that 19% of the 
respondents had ever heard of PrEP and that lower educational attainment, no individual costs, 
and minimal side effects correlated with higher probability of using PrEP to reduce risk of HIV 
infection (Mimiaga, et al., 2009). A survey of 1819 MSM in California found that only 16% of 
the respondents had PrEP awareness and unprotected sex and sex under the influence of a drug 
were positively associated with PrEP awareness (Liu, et al., 2008). Out of the 4 survey sites, 
African American participation ranged from 3-8% of the sample population and only 12% of the 
African American respondents reported PrEP awareness (Liu, et al., 2008). 
Several examples have been provided from the literature which surveyed MSM 
knowledge, attitudes, and perceptions on PrEP. Despite the wealth of information that these 
studies provide, they are not without limitations. Most of these surveys were conducted prior to 
the release of the iPrEX results and PrEP efficacy among MSM. Also, a majority of these 
surveys have few Black MSM in the sample, less than the incidence and prevalence of HIV 
being observed in Black MSM. Limited research exist post PrEP efficacy and/or recruits a larger 
sample of Black MSM on their knowledge and likeliness to use PrEP as a method to prevent 
HIV infection. The HPTN 061, Broadening the Reach of Testing, Health Education, Resources 
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and Services for Black MSM (BROTHERS) study enrolled Black MSM from sites in Boston, 
Atlanta, Washington DC, New York City, Los Angeles, and San Francisco. The study population 
was diverse in demographic factors such as educational attainment, recruited both HIV positive 
and negative participants and the mean age was 39. Only 9.5% of the sample had knowledge of 
PrEP with knowledge ranging from 7.0% in Los Angeles to 14.5% in New York City (HIV 
Prevention Trials Network, 2011). Despite overall PrEP knowledge being low in the sample, 
these observed regional differences may need to be addressed in terms of the dissemination of 
health information. Publications from results of the BROTHERS study have yet to be released. 
Prior to PrEP efficacy studies, information exist that MSM have been using PrEP via self- 
medication from an HIV positive person without a prescription. MSM were surveyed at minority 
gay pride events in 2004 in Oakland, CA, Detroit, MI, Baltimore, MD, and San Francisco, CA 
on their knowledge of PrEP and if they had ever used PrEP. The study recruited 1041 people, 
43% who were Black; the study found that in the overall sample the knowledge of PrEP was 
 
25% with Black MSM being most likely to ever report using PrEP (Kellerman, et al., 2006). The 
same study at minority gay pride events was replicated in 2005 and 2006 yielding similar results 
to the 2004 study. Participants were recruited from events in San Franciso, CA, Jackson, MS, 
Charlotte, NC, St. Louis, MO, Washington DC, Chicago, IL, and Detroit, MI. 78% of the entire 
sample which included HIV positive and negative individuals was Black. Among the sample of 
356 self-reported HIV negative individuals who took the survey PrEP and PEP knowledge was 
 
19.7% among the African American participants (Voetsch, et al., 2006). Prior studies have been 
conducted that recruited a majority of MSM to determine knowledge, attitudes, and likeliness to 
use PrEP. Despite these were conducted pre PrEP efficacy and used PrEP and PEP concurrently 
during data collection and analysis. 
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2.2.6 The Internet as a Portal for HIV Research and Intervention 
 
 
 
 
The Internet has the potential to be a cost effective method of HIV education, research, 
and health promotion. Data collected from the Pew Research Center suggests that 79% of 
Americans have internet access and 83% have used the internet at least once to obtain health 
related information (Glickman, et al., 2012). The current study rationale for using the internet as  
the  setting  and  for  recruitment  was  the  perceived  benefits  and  low  difficulty.  Prior 
evidence  also  suggests  that  online  interventions  have  been  effective  in  reducing  risk 
behaviors such as smoking cessation and obesity (Chiasson, et al., 2010). 
MSM seek sex online more frequently than other sexual groups and evidence 
suggests that MSM who seek sex online report more sexual partners, casual sex, and unprotected 
anal intercourse (Chiasson, et al., 2010). The internet is a portal for the transmission of HIV and 
provides opportunity for intervention among high risk MSM for research and education. The 
internet can facilitate HIV prevention initiatives and linkage to testing, treatment, and health 
information. MSM chat room intervention with health educators have a positive impact of 
internet outreach on HIV testing, risk reduction, education, and social support (Rhodes, 
2004). The Student Health Action Coalition Against HIV (SHAC-HIV) at the University of 
 
North Carolina at Chapel Hill used online outreach to link high risk MSM to testing with a 
 
2.3% positivity rate (Feldacker, et al., 2010). With the current HIV epidemiological figures 
suggesting that 1 in 5 individuals in the US being HIV positive and unaware of their status, 
online outreach has the potential to find undiagnosed cases. HIV prevention must adapt to the 
dynamics of the epidemic which means that the internet and other technologies must be utilized 
for prevention. 
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The internet has the opportunity to reach marginalized MSM. Bowen, et al. (2008), 
conducted a randomized control trial as an online intervention resulting in acceptability 
among MSM and efficacy in risk reduction among rural MSM. The presence of Black MSM 
on hookup and social networking sites provides an opportunity to this population in novel 
and untraditional ways. With the input of Black MSM, HEALTHMPOWERMENT.ORG 
was created as a tailored and culturally appropriate online intervention for young Black 
MSM and serves as a model for future initiatives (Hightow-Weidman, et al., 2011). Future 
HIV prevention initiatives must utilize the potential that the internet and other technologies 
such as cell phone applications and text messaging provide in accessing at risk populations. 
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3.0 METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1 CURRENT STUDY 
 
 
 
 
The objective of the current study was to ascertain the knowledge, attitudes, and beliefs 
of Black MSM on PrEP as well as self-perceived susceptibility to HIV infection. The current 
study is approved by the University of Pittsburgh Institutional Review Board, study number; 
TPRO11110431. Participants were recruited for an online survey between the dates of January 
13th, 2012 and January 30th 2012. The survey link also remained open during this period. There 
 
were a few questions which were essential to data analysis; what is your knowledge of PrEP? 
Currently, would you take a pill daily to reduce your risk of HIV infection? What is your risk of 
HIV/STD infection? The rationale for the current study was developed during the author’s 
master’s practicum at the Pittsburgh AIDS Task Force working with the Man 2 Man Project 
(M2M), a behavioral intervention addressing substance use and high risk sexual behaviors in 
MSM. 
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3.2 METHODS 
 
 
 
 
A quantitative method of survey was used in the analysis of the current study. Survey 
participants were allowed to answer some of the questions open ended yet many did not. A 
survey was chosen as the instrument of data collection for several reasons. First, cross sectional 
surveys have shown to be effective in capturing a snapshot and determining very important 
health information from populations. Surveys are less invasive and usually less time consuming 
than other methodologies which can result in increased participation and higher retention rates in 
research. Lastly, due to limited fiscal resources the use of a survey was cost effective, practical, 
and appropriate for the current study. 
Wording  of  the  survey  was  essential  for  readability  and  cultural  relevance  of  the 
questions. Therefore the author used prior experiences with the MSM population to word 
questions appropriately. The survey was not tested for reliability and validity. Individuals were 
consulted who were either MSM or conducting HIV prevention research for technical assistance. 
Per the suggestion of Jonathon Baker of the Microbicide Trials Network, a Likert scale was used 
on many of the survey questions. A Likert scale of 1-10 was used on the survey to give 
respondents a broader range of options in answering the survey questions. It was appropriate to 
use a Likert scale for the survey given that a majority of the questions were of a participant’s 
perception of what was being asked. 
Ultimately, the author had the final decision of how survey questions were worded and 
which questions were on the survey. Many of the suggestions made by consultants were taken 
into consideration in the survey development. Prior studies that have been conducted provided 
formal explanations of PrEP prior to asking respondents knowledge and awareness of PrEP. 
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Questions were formulated and structured so respondents were asked of their knowledge on 
PrEP after they were asked if they would take a daily pill to reduce their risk of HIV infection. 
More information on the wording and structure of the survey may be found in Appendix A. 
 
 
 
 
 
3.2.1 Setting 
 
 
 
 
The surveys were disseminated online using the social networking sites Twitter and 
Facebook. Social networking sites have the potential to draw large survey samples as well as 
disseminate health information. Social networking outreach and marketing is currently being 
used by many entities in HIV prevention because of the increasing number of people who are 
present on these sites. An estimated 75% of Americans aged 18-29 are using social networking 
which corroborates the epidemiology of HIV infection and high risk sexual behaviors (Chiasson, 
et al., 2010). Constructing and disseminating a survey instrument online was relatively easy and 
facilitated optimal sampling and participant anonymity. 
 
 
 
 
 
 
 
 
3.2.2 Eligibility 
 
 
 
 
Eligibility in the current study was contingent upon participant self-reported response of 
being over the age of 18, HIV negative or unaware of HIV status, Black/African American, and 
MSM. A stratified sample was selected in order to collect the most information possible about 
the sample population. As a consequence of strict eligibility requirements, results may not be 
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generalized to other populations. Despite teenagers over the age of 18 being able to give consent 
to an HIV test, they were excluded from the sample because of the online setting and to prevent 
obstacles from obtaining informed parental consent. Only MSM were allowed to take the study 
since the iPrEX efficacy trials were conducted among MSM thus external validity is contingent 
amongst MSM populations. HIV positive individuals were excluded from the sample since many 
of the questions on the survey were about pre-exposure prophylaxis of HIV in HIV negative 
individuals. Including HIV positive individuals in the sample may have introduced confounding 
and biases into the sample population subsequently affecting external and internal validity. 
 
 
3.2.3 Recruitment 
 
 
 
 
The author wanted to recruit from the MSM hookup websites BlackGayChatLive 
(BGCLive) and Adam4Adam and was unable to do that because of costs. This is a possible 
limitation of the sample potentially because a larger pool of respondents could have been 
achieved. Participation for the survey was solicited with a script which included an explanation 
of survey as a tool for research, time required to complete, respondent anonymity, and minimal 
risks. The script can be found in appendix B. Social networking sites provide the opportunity for 
the dissemination of information. The author being a part of the Black MSM community utilized 
a following of members of Facebook and Twitter to recruit for and disseminate the survey. The 
survey script along with the embedded link was sent to an initial wave of individuals whom the 
author knew were MSM but did not know personally. These individuals were solicited for 
participation in the study as well as to recruit other participants. At their discretion, participants 
subsequently posted the survey link on their profile and forwarded to their friends.  Since the 
survey  was  anonymous,  the  author  retains  no  information  on  which  participants  actually 
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completed the survey or actively recruited other participants. To ensure that one individual 
would not complete the survey multiple times, IP addresses were checked for duplication during 
data analysis in which none were found. 
 
 
3.2.4 Consent 
 
 
 
 
Prior to beginning the survey, respondents provided consent to taking the survey and 
answered the screening questions correctly. Participants were provided a script which included 
statements that the survey was for research, took approximately 5 minutes to complete, 
explanation of risks to the respondent, and notified respondents that they had no obligation to 
complete the survey. Participants were also notified that the survey was anonymous and that no 
personally identifiable information would be collected. A total of 2 participants did not consent 
to  the  survey  with  others  dropping  out  before  survey  completion.  Participants  who  were 
ineligible for the study were forwarded to a disqualification page where they were provided 
access to information on PrEP, HIV testing, and other resources including my contact 
information. 
 
 
 
 
 
3.2.5 Incentive 
 
 
 
 
There was no compensation or incentive for participants to complete the survey. There 
were limited resources to provide respondents with incentives and providing incentives may have 
introduced bias into the study. The lack of an incentive did not appear to have an effect on 
participation and it is likely that respondents participated because of the relatively ease of 
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questions, the amount of time needed to complete the survey, and the possible utility of the 
research. 
 
 
3.2.6 Data Collection 
 
 
 
 
The author created an account with Survey Monkey, a secure website for survey 
development and dissemination and it also provides encrypted data storage capabilities. The data 
was monitored daily throughout the course of the study to observe participation and to assure 
participant confidentiality. Throughout the course of the study there were no breaches in 
confidentiality. The author had sole access to the Survey Monkey account and the data which 
was accessed from an encrypted personal laptop computer. Upon the completion of the study, the 
survey was closed, preventing the collection of any further responses. All of the data was 
compressed in a excel zip file and saved a personal computer. Data was integrated from the excel 
file into Software Package for the Social Sciences (SPSS) software for analysis. After IP 
addresses were scanned for duplication, they were deleted from the file spreadsheet. 
 
 
3.2.7 Confidentiality 
 
 
 
 
Ensuring confidentiality was paramount to the survey participation and retention. 
Participants  were  asked  personal  information  such  as  HIV  status  and  sexual  history.  No 
personally identifiable information collected during any section of the survey. Several survey 
questions   allowed   open   ended   responses   which   could   have   been   an   opportunity   for 
confidentiality breaches. Participants were informed of their anonymity in the survey in both the 
recruitment scripts and informed consent. No personal identifiers were left by participants on the 
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survey and if they had, participants were notified in the informed consent process that those 
responses would have been deleted. Participant Feedback 
Per  IRB  requirements,  the  author’s  personal  contact  information  was  placed  on  the 
survey so respondents could forward all concerns to the author. There was one instance noted 
when a participant was very upset with the survey questions. The participant contacted the author 
via email and stated that he felt the survey questions were very offensive. The author promptly 
responded to the respondent apologizing to the participant if he felt the survey questions was 
offensive to him. The author also reiterated to the participant that he did not have any obligation 
to complete the survey and could discontinue you at any time. Follow up with the participant 
thus ended and the anonymity of the participant was retained. 
 
 
3.2.8 Data Analysis 
 
 
 
 
All of the survey data that was collected on Survey Monkey was downloaded from the 
server  and  formatted  into  a  Microsoft  Excel  spreadsheet.  The  data  was  then  cleaned  in 
preparation for transport to SPSS. Participant responses that were ineligible from the survey were 
deleted from the spreadsheet to be used for analysis as well as participants who did not complete 
the  survey.  These  responses  were  deleted  because  both  the  dependent  and  independent 
variable(s) were unable to be ascertained for analysis. Age responses were recorded as separate 
questions on the Survey Monkey server; therefore a new variable and column for participant age 
was created to facilitate data translation into SPSS. Survey questions were also coded into 
variable names so that it could be formatted in a SPSS spreadsheet and to facilitate analysis. 
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3.2.9 Limitations 
 
 
 
 
The current study has some limitations which should be mentioned. Firstly, the study is a 
sample  of  Black/African  American  MSM,  thus  the  results  from  the  study  may  not  be 
generalizable to MSM of other races and ethnicities. Secondly, all MSM are not either online or 
have accounts on Facebook and Twitter, therefore a percentage of MSM were unable to be 
reached from the recruitment methods used. Participants were also asked questions about past 
behaviors which they may have under or overestimated, resulting in the introduction of recall 
bias into the sample. The survey instrument was not tested for reliability and validity and would 
need further refinement and testing for future dissemination. Respondents were not recruited 
from a specific geographic were participants asked about their residence. This was done in 
attempt by the author to limit bias as much as possible and to protect the participant 
confidentiality.  Not  collecting  geographic  location  is  a  limitation  and  may  affect  external 
validity. However, results from the Global iPrEX trial showed that geographic location did not 
confound the study results. The epidemiology shows that Black MSM in the United States are 
currently the highest at risk group for HIV infection, therefore the pool was drawn from this 
population. 
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4.0  RESULTS 
4.1 SAMPLE 
 
The original, raw sample included individuals who were ineligible for the survey 
however, it is important to note the self-reported HIV status of the participants. Out of 156 
respondents who responded on HIV status, 32 or 20.5% reported being HIV positive. This is an 
important finding because it supports the HIV epidemiology that 1 in 5 MSM are HIV positive. 
After eligibility was determined, a total of 118 participants began the survey, with 99 participants 
completing the survey with a response rate of 83.9%. The table below provides the age of the 
sample. 81.8 % of the sample was between the ages of 18-30 years old. This may have positive 
implications on the external validity of the results because currently Black MSM age 18-29 has 
the highest disparity of HIV incidence. It is possible that older MSM were not heavily 
represented in the sample because they are not on Facebook and Twitter and were not reached 
through recruitment efforts thus weakening external validity of their results. 
 
 
 
 34 
Table 1. Participant Age 
 Frequency Percent Cumulative 
Percent 
 
18 - 24 35 35.4 35.4 
25 - 30 46 46.5 81.8 
31 - 40 13 13.1 94.9 
41 - 50 4 4.0 99.0 
50+ 1 1.0 100.0 
Total 99 100.0  
 
4.2 PREP 
One of the main objectives of the current study was to ascertain whether Black MSM 
would use PrEP to risk their risk of HIV infection and to assess their knowledge of PrEP. Table 2 
represents a cross tabulation of the respondent knowledge and acceptance of PrEP. Acceptance 
was ascertained from the survey question “Currently, if I could reduce my risk from getting HIV 
by taking a pill daily, I would.” The responses were logged on a 1-10 scale and for analysis 
purposes consolidated into a variable parameter set by the author. For the question on PrEP 
acceptance 1-2 equaled strong disagreement with the question, 3-4 (somewhat disagree), 5-6 
(neither agree nor disagree). (7-8) somewhat agree), and 9-10 (strongly agree). Since there were 
fewer respondents who reported moderate knowledge of PrEP, 1-3 equaled no knowledge of 
PrEP, 4-6 (little), 7-8, (moderate), and 9-10 (great).Table 2 shows that 56.4% of the sample at a 
95% confidence interval of 9.77 (46.63- 66.16) reported having little or no knowledge of PrEP 
yet would use PrEP to reduce their risk of HIV infection. On the other hand, of the 18.2% of the 
sample that had moderate or great knowledge of PrEP, 10% of these respondents reported that 
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they were either unsure or in some level of disagreement of using PrEP to reduce risk of HIV 
infection.  
Table 2. PrEP Acceptance and Knowledge 
 PrEP Knowledge, % (n=99) Total 
None Little Moderate Great 
PrEP 
Acceptance 
Strongly Disagree 4 (4.0) 2 
(2.00) 
2 (2.00) 1 (1.0) 9 (9.1) 
Somewhat Disagree 2 (2.0) 0 
(0.0) 
0 (0.0) 1 (1.0) 3 (3.0) 
Unsure 9 (9.1) 6 
(6.0) 
3 (3.0) 3 (3.0) 21 
(21.2) 
Somewhat Agree 7 (7.0) 11 
(11.1) 
1 (1.0) 1 (1.0) 20 
(20.2) 
Strongly Agree 31 
(31.3) 
9 
(7.0) 
3 (3.0) 3 (3.0) 46 
(46.5) 
Total 53 
(53.5) 
28 
(28.3) 
9 (9.1) 9 (9.1) 99 (100) 
*Percentages are in parentheses   
Participants were asked if they were willing to pay full out of pocket costs for PrEP to 
prevent them from getting HIV. Truvada is thought to cost about $36 a day or $13,000 annually 
and it was these figures that were used in the survey question. 49.5% of the sample stated that 
they were strongly against paying out of pocket costs for PrEP while another 37.1% were unsure.  
 
Table 3. PrEP Costs 
 Frequency Percent Cumulative 
Percent 
 Strongly 
Disagree 
49 7.1 49.5 
Somewhat 
Disagree 
9 3.0 58.6 
Unsure 30 2.0 86.9 
Somewhat 
Agree 
4 1.0 90.9 
Strongly Agree 9 8.1 100.0 
Total 99 100.0  
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4.3 RISK BEHAVIORS 
 
In order to ascertain respondent self-perceived susceptibility to HIV infection, it was 
hypothesized that a respondents lower self-perceived susceptibility to HIV and had little or no 
knowledge on PrEP would result in lower PrEP acceptance. Table 4 below shows the cross 
tabulation of respondent self-perceived susceptibility and condom use. 58.6% of the sample 
strongly agreed that they used condoms during anal intercourse whether insertive or receptive. 
43.4% of the sample felt that their susceptibility to HIV infection was either no or low risk 
however, 72.1% or 31 respondents from this stratified population strongly agreed that they use 
condoms during anal intercourse. Participants were also allowed to enter non-applicable and 
leave an open ended response on this question. Four participants answered N/A and their 
responses were as followed: 
“I am a virgin, 20 years of virginity” 
“I’ve only had anal sex with one person for the past 3 years, monogamous relationship in that 
regard” 
“I typically use a condom when having sex, however, with my current, long-term partner, I 
don’t” 
“Not all of the time” 
 
These numbers reveal that respondents already possess some level of information on HIV 
prevention and are aware that condoms are an effective primary prevention method.  
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Table 4. Self-Perceived Susceptibility for HIV Infection and Condom Use 
 Condom Use Total 
Strongly 
Disagree 
Somewhat 
Disagree 
Unsure Somewhat 
Agree 
Strongly 
Agree 
Self -
Perceived 
Risk 
No Risk 1 0 0 0 12 5 
Small 3 4 1 3 19 26 
Unsure 1 2 1 4 10 8 
Moderate 1 3 0 7 8 14 
Great 0 0 2 4 9 10 
Total 6 9 4 18 58 99 
 
HIV testing is important to prevention and would be vital to implementing PrEP as a 
prevention strategy. Participants were asked the degree to which they agreed with the statement 
“I get tested for Human Immunodeficiency Virus (HIV) at least once or twice a year.” 58.6% of 
the sample either strongly or somewhat agreed that they get tested for HIV at least once a year. 
16.2% of the sample strongly or somewhat disagreed that they were tested at least once or twice 
a year for HIV. While not a significant percentage of the sample, individuals in this group may 
be engaging in riskier sexual behaviors and/or are unaware of their HIV infection. Another 
explanation for individuals who are not tested regularly could be an issue of access. More 
information should be gathered on the reasons why MSM are tested or not. 
Table 5. Annual HIV Testing 
                           Frequency Percent Cumulative 
Percent 
Strongly 
Disagree 
12 4.0 12.1 
Somewhat 
Disagree 
4 1.0 16.2 
Unsure 7 2.0 23.2 
Somewhat 
Agree 
18 1.0 41.4 
Strongly Agree 58 51.5 100.0 
Total 99 100.0   
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4.4 ANALYSIS OF VARIANCE 
To ascertain the relationship of different independent variables measured on the 
dependent variable of PrEP acceptance, the author chose a univariate regression analysis. In each 
model, I added more independent variables and it was determined if the variable was statistically 
significant and how much variance was explained in the relationship of the independent variables 
on the dependent variable. If an independent variable was statistically insignificant in all of the 
models in which it was included then it was removed from the analysis in the 5th model. Condom 
use, substance use influencing high risk sexual behaviors, HIV testing, and concern with HIV 
were all statistically insignificant in each model they were included thus having minimum 
influence on whether or not a respondent would take a daily pill to reduce their risk of HIV 
infection. Age appeared to be the strongest indicator across all models of PrEP acceptance. PrEP 
costs were more statistically significant than age in the two models in which it was included in 
the analysis with age. Model 4, which included all of the independent variables observed had an 
r-squared value of 0.387, thus explained 38.7% of the variance between the independent 
variables and the dependent variable. 
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Table 6. Regression Analysis of Covariates Influencing PrEP Acceptance 
 
Independent Variables Model 1 Model 2 Model 3 Model 4 Model 5 
      
Age 3.115* 3.529** 6.901* 17.593* 18.820* 
Self-Perceived Risk 7.334** 8.116* 2.933** 1.828 1.512 
HIV Concern 0.189 0.170 0.165 0.002  
Black MSM  2.344 2.286 3.282** 5.355* 
STD Prevention  0.561 0.593 3.441** 3.105** 
Condom Use   0.014 0.217  
HIV Test   0.113 0.805  
Substance Use   0.001 0.941  
PrEP Knowledge    2.410  
PrEP Attitude    7.204* 9.613* 
PrEP Cost    21.756* 19.191* 
      
R² 0.087 0.120 0.121 0.387 0.350 
      
* Significant at α = .05      
** Significant at α = 0.1      
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5.0  DISCUSSION 
 
PrEP has the potential to be a promising HIV prevention strategy among Black MSM. 
Despite having little knowledge on PrEP, Black MSM are willing to use PrEP to reduce their risk 
of HIV infection. This has been a consistent finding throughout the literature and further research 
is needed to ascertain other variables responsible for this relationship. Black MSM also desire to 
be educated on PrEP. If PrEP is used among Black MSM, the medications will likely have to be 
provided at little to no cost to the recipient. Currently, the costs of PrEP medications are either 
paid for in part by private medical insurance providers and or out of pocket. It is highly unlikely 
that young Black MSM will have the capacity to pay out of pocket costs for PrEP, therefore 
alternative methods must be explored such as drug subsidies. PrEP education and awareness 
must be heightened and integrated with existing HIV prevention methods. It is important that 
MSM have access to health literature, information, and counseling that promotes the use of 
condoms as an effective primary prevention behavior against the transmission of HIV as well 
routine HIV testing and awareness of HIV status. 
 The CDC has yet to release formal guidelines on PrEP. In interim guidance 
recommendations the CDC suggests that “PrEP must be obtained and used in close collaboration 
with healthcare providers to ensure regular HIV testing, risk reduction and adherence counseling, 
and careful safety monitoring. Anyone considering PrEP should speak with their doctor (CDC, 
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2011).” Given the current climate of healthcare access and coverage in the U.S. with over 40 
million lacking healthcare insurance, it is likely that many young Black MSM will not have a 
primary care physican in which they see regularly if at all. In addition to primary care physicians, 
these guidelines should be extended to include building the capacity of community based 
organizations and health centers to edcucate and serve individuals who may inquire about PrEP. 
Research on PrEP acceptability and effectiveness is ongoing and it essential that until more 
formal guidelines becomes available, PrEP is not publicized as a silver bullet to prevent HIV. 
Instead PrEP should be promoted as an additional line of defense against HIV infection to be 
used in conjunction with condom use, HIV testing, and adherence.  
PrEP implementation also does not come without some ethical considerations as well. As 
of March 15, 2012, there were 3,840 HIV positive individuals on the AIDS Drug Assistance 
Program (ADAP) waiting list (TheBody.com, 2012). These individuals need HIV medications to 
survive and do not have the financial capacity to pay for the medications. In 2011, the HIV 
Prevention Trials Network Study 052 better known as “Treatment as Prevention” showed that an 
earlier HIV diagnoses and initiation of treatment resulted in a significant reduction in 
transmission to infected partners. A cost benefit analysis of the effectiveness of HIV treatment 
versus PrEP may need to be conducted to determine how both may be used in conjunction most 
appropriately to reduce new infections and improve the health and quality of life of infected 
individuals. PrEP has the potential to be advantageous to the HIV prevention toolbox. More 
biomedical, social, and economical research is needed for most effective and appropriate use. 
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5.1 RECOMMENDATIONS 
5.1.1 Prior Studies 
Voetsch et.al (2006) recruited Black MSM from minority gay pride events and found that 
knowledge of PrEP was relatively low regardless of age. A limitation of the results is that 
knowledge of PrEP and PEP were asked concurrently therefore it is possible that more 
respondents actually had awareness of PEP rather than PrEP. Nevertheless awareness of PrEP 
alone is unable to be ascertained from the results. Also the study was conducted prior to the 
release of PrEP efficacy amongst MSM which also may outdate the results.  
The 2002 BROTHERS study (HPTN 062) also found PrEP knowledge to be low amongst 
Black MSM, however PrEP acceptance was not studied. Also HIV positive indiviudals were 
included in the sample which could confound the results. Having a person who is already HIV 
positive and asking them questions about preventing HIV in uninfected individuals who 
introduce bias into study results. MSM minorities having higher PrEP acceptance concurrent 
with little knowledge has been replicated in the literature. Many of the variables explored are 
demographic variables such as educational attainment and income however, behaviors, 
perception of risks, and knowledge are collected to ascertain the explanation of the relationship 
or variance in regards to PrEP acceptance.  
Demographic infomation undoubtedly are important variables to collect however, these 
studies did not conduct variance analyses to ascertain whether or not these variables had any 
influence on PrEP knowledge or acceptance. Overall, there has been very little research 
published in the literature post PrEP efficacy assessing the knowledge and attitudes that MSM 
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have towards PrEP. With several PrEP demonstration and acceptibility projects ongoing and in 
planning, it is expected that more information will be gathered in the near future.  
5.1.2 Current Study 
A large percentage of Black MSM are aware of HIV prevention strateges and are already 
implementing them in their daily lives. There is a population of Black MSM however, who are 
taking risks and likely putting themselves at risk of HIV infection through unprotected anal 
intercourse and  not being aware of their status. Despite lacking basic knowledge on PrEP, Black 
MSM are willing to use PrEP to reduce their risk of HIV infection. A possible explanation is the 
wording of the survey questions. Participants were not given any prior information on PrEP other 
than it is preventing the transmission of HIV in uninfected  individuals. Without any explanation 
of risks or benefits of PrEP, respondents may have been predisposed to acceptance to some 
extent.  In terms of the out of pocket costs of PrEP, Black MSM are unwilling to pay for 
mediciations, bringing up the discussion of how PrEP will be funded if used to reduce the risk of 
transmission and incidence.   
Currently, HIV prevention funding is strained throughout the country and providing PrEP 
at no cost outside of any ongoing studies is highly unlikely. Analysis of variance was an 
appropriate method of analysis for the current study in order to observe the relationships and 
interactions of the independent variables on PrEP acceptance. Relevant behavioral data on 
participants was prioritized for the current study rather than demographic data. Results from the 
current study show that risk behaviors have minimal influence on the acceptance of PrEP 
amongst Black MSM and that age is the strongest predictor of PrEP acceptance. Despite an 
extensive number of variables being observed, an ideal explanation of variance was not achieved 
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suggesting that there are other variables not included in the current study which may influence 
PrEP acceptance. 
5.1.3 Comparison of Studies 
In comparison with other studies, the current study supports prior evidence that Black 
MSM have little knowledge on PrEP but are likely to use it reduce their risk of HIV infection. 
Prior studies have concluded that PrEP acceptance and knowledge is influenced by high risk 
sexual behaviors, race, educational attainment, and income. The current study has collected more 
information on risk behaviors, perceptions and attitudes of HIV/STD infection, PrEP, and anal 
intercourse to study correlation with PrEP acceptance. The current study is timelier in that it was 
conducted post PrEP efficacy among MSM and has sampled from the population which current 
epidemiological figures show the highest disparity of incidence.  
The current study took a different approach in comparison to prior studies in that the 
sample recruited had specific eligibility requirements, one being that HIV positive individuals 
were excluded from the analysis. The current study sample also included exclusively African 
American MSM which has had relatively lower levels of participation in prior studies and 
clinical trials. Different variables were explored under the current study that collected knowledge 
and attitudes on PrEP, in addition to behaviors and perceptions which are lacking in previous 
studies. A wider compendium of variables was collected to determine independent variable and 
covariate relationships on PrEP acceptance. The current study also had a large percentage of the 
sample that were between the ages of 18-30 which is much younger than the mean age of prior 
studies and increases generalizability of study results to this age group. 
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6.0  CONCLUSIONS 
 
6.1 SUMMARY 
 
HIV incidence among African American MSM is increasing at alarming rates as 
compared to other MSM racial cohorts. HIV prevention intervention has traditionally included 
evidence based behavioral interventions, risk reduction, and capacity building. Biomedical 
interventions such as oral pre-exposure prophylaxis have the potential to be another weapon 
included in the prevention arsenal. PrEP implementation does not come without concern 
however; efficacy among MSM is less than ideal, little information exists on potential long term 
effects, cost effectiveness and feasibility have yet to be ascertained, and it is unlikely that 
financial assistance will be available or sufficient which could result in PrEP use almost 
exclusively among those who can afford it. 
 PrEP alone cannot alleviate the HIV epidemic among African American MSM. PrEP 
must be touted as an additional line of defense of HIV transmission to be used concurrently with 
condoms, routine HIV testing, risk reduction, capacity building, education, awareness, and 
intervention. Despite possessing little knowledge of PrEP, Black MSM are willing to use PrEP to 
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reduce their risk of HIV infection if they are not required to pay out of pocket expenses. One 
explanation for these findings is that due to the function of the survey instrument, respondents 
were unaware of the risks and benefits of PrEP and more inclined to acceptance. One thing that 
is undisputed from prior research is that acceptance is relatively high among Black MSM. The 
current study was able to ascertain some of these reasons. More research and information must 
be conducted around PrEP and there must be higher recruitment and retention of Black MSM in 
these studies. 
6.2 PUBLIC HEALTH SIGNIFICANCE  
 
With over a million people living with HIV and over 50,000 new infections annually, 
reducing the incidence of HIV in the US is a public health priority. The National HIV/AIDS 
Strategy states that “Not every person or group has an equal chance of becoming infected with 
HIV. Yet, for many years, too much of our Nation’s response has been conducted as though 
everyone is equally at risk for HIV infection (2010).” The highest disparity of HIV infection is 
among African Americans and young African American MSM bear the highest percentage of the 
burden. It is estimated the medical expenditures that a HIV positive accrues over a lifetime 
exceeds 500,000 dollars. Biomedical prevention strategies such as pre-exposure prophylaxis are 
promising to reducing the number of infections among Black MSM and ensuing healthcare costs. 
Integrating knowledge, awareness, and possible implementation of PrEP among Black MSM will 
require a concerted, collaborative effort involving federal agencies, pharmaceutical companies, 
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community based and AIDS service organizations, local and state health departments, Black 
MSM groups, and medical providers. 
The findings from this study may not be applicable to all African American MSM 
however; insight is provided on the dynamics of HIV infection and prevention strategies among 
this population accessed through the collection of information on behaviors, knowledge, and 
perceptions. The study can provide information that can guide public health practice and 
biomedical HIV prevention efforts targeted to Black MSM. Lastly, this study contributes greatly 
to the little information that exists on Black MSM knowledge and acceptance of pre-exposure 
prophylaxis.  
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APPENDIX A 
 
 
 
 
 
 
 
 
 
SURVEY OF THE CURRENT STUDY 
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The picture used in the survey instrument is from the Brothers Study (brothersstudy.com , 
2011).  
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APPENDIX B 
 
SURVEY RECRUITMENT SCRIPT 
 
 
 
 
Hey, can you please take 5 minutes and fill out this anonymous survey for my thesis 
research which is for Black/African American men who have sex with men (MSM). I would 
greatly appreciate it. The survey asks some very personal questions however, risks of completing 
the survey are minimal and you are able to discontinue taking the survey at any time. Please do 
not put any personally identifiable information on the survey (ex: Name, Phone number, etc.). If 
you could also forward the survey to a minimum of two of your friends on Facebook and/or 
Twitter. Thanks! (Link for informed consent followed by embedded survey link will be placed 
here)   
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